Skip to content

Author

Peng Wang

We have 2 of 11 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice

A central argument about treatment sequencing is advanced: because CLDN18.2 expression declines progressively under therapeutic pressure, continuous target-plus-chemotherapy acts on an eroding antigen substrate, for patients with high, homogeneous baseline expression, an early intensive induction followed by CLDN18.2-d...

Yu-Tao Xia, Ming-Fang Wang, Tao-Sheng Huang et al. · 0 citations
Open access Aug 2026

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Osimertinib plus chemotherapy significantly increased progression-free survival among patients with EGFR-mutated advanced NSCLC harboring concurrent TP53 mutations, and provided a clinical rationale for individualized combination strategies in the management of patients with EGFR-mutated NSCLC.

Ting Zhou, Huaqiang Zhou, Fangfang Gao et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.